Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

44 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
SARS-CoV-2 viral load is associated with increased disease severity and mortality.
Fajnzylber J, Regan J, Coxen K, Corry H, Wong C, Rosenthal A, Worrall D, Giguel F, Piechocka-Trocha A, Atyeo C, Fischinger S, Chan A, Flaherty KT, Hall K, Dougan M, Ryan ET, Gillespie E, Chishti R, Li Y, Jilg N, Hanidziar D, Baron RM, Baden L, Tsibris AM, Armstrong KA, Kuritzkes DR, Alter G, Walker BD, Yu X, Li JZ; Massachusetts Consortium for Pathogen Readiness. Fajnzylber J, et al. Among authors: tsibris am. Nat Commun. 2020 Oct 30;11(1):5493. doi: 10.1038/s41467-020-19057-5. Nat Commun. 2020. PMID: 33127906 Free PMC article.
Lymphoma diagnosis and plasma Epstein-Barr virus load during vicriviroc therapy: results of the AIDS Clinical Trials Group A5211.
Tsibris AM, Paredes R, Chadburn A, Su Z, Henrich TJ, Krambrink A, Hughes MD, Aberg JA, Currier JS, Tashima K, Godfrey C, Greaves W, Flexner C, Skolnik PR, Wilkin TJ, Gulick RM, Kuritzkes DR. Tsibris AM, et al. Clin Infect Dis. 2009 Mar 1;48(5):642-9. doi: 10.1086/597007. Clin Infect Dis. 2009. PMID: 19191652 Free PMC article. Clinical Trial.
Evolution of CCR5 antagonist resistance in an HIV-1 subtype C clinical isolate.
Henrich TJ, Tsibris AM, Lewine NR, Konstantinidis I, Leopold KE, Sagar M, Kuritzkes DR. Henrich TJ, et al. Among authors: tsibris am. J Acquir Immune Defic Syndr. 2010 Dec;55(4):420-7. doi: 10.1097/QAI.0b013e3181f25574. J Acquir Immune Defic Syndr. 2010. PMID: 20856130 Free PMC article.
Xenotropic murine leukemia virus-related virus prevalence in patients with chronic fatigue syndrome or chronic immunomodulatory conditions.
Henrich TJ, Li JZ, Felsenstein D, Kotton CN, Plenge RM, Pereyra F, Marty FM, Lin NH, Grazioso P, Crochiere DM, Eggers D, Kuritzkes DR, Tsibris AM. Henrich TJ, et al. Among authors: tsibris am. J Infect Dis. 2010 Nov 15;202(10):1478-81. doi: 10.1086/657168. Epub 2010 Oct 11. J Infect Dis. 2010. PMID: 20936980 Free PMC article.
Vicriviroc resistance decay and relative replicative fitness in HIV-1 clinical isolates under sequential drug selection pressures.
Tsibris AM, Hu Z, Paredes R, Leopold KE, Putcharoen O, Schure AL, Mazur N, Coakley E, Su Z, Gulick RM, Kuritzkes DR. Tsibris AM, et al. J Virol. 2012 Jun;86(12):6416-26. doi: 10.1128/JVI.00286-12. Epub 2012 Apr 4. J Virol. 2012. PMID: 22491471 Free PMC article. Clinical Trial.
We previously described an HIV-1-infected individual who developed resistance to vicriviroc (VCV), an investigational CCR5 antagonist, during 28 weeks of therapy (Tsibris AM et al., J. Virol. 82:8210-8214, 2008). To investigate the decay of VCV resistance mutations, …
We previously described an HIV-1-infected individual who developed resistance to vicriviroc (VCV), an investigational CCR5 antagonist, durin …
44 results